

Embargo: 00:01 2nd February 2026

Press Release

IBSA UK&I launches Perovial[®]: the first licensed injectable option for men with acute Peyronie's disease

A clinically supported option for early intervention in a historically underdiagnosed and undertreated condition.

Watford, UK – IBSA UK&I today announces the launch of Perovial[®], the first licensed hyaluronic acid injectable indicated for the management of Peyronie's disease (PD) in its acute phase. Perovial[®] offers healthcare professionals a new, evidence-based option for men presenting with early symptoms of Peyronie's disease, helping to address long-standing gaps in treatment.

PD is a chronic, progressive condition characterised by penile curvature, deformity, pain and erectile dysfunction, resulting from plaque formation within the tunica albuginea^{1,2,3}. Estimates suggest it affects between 0.3% and 13.1% of men worldwide⁴, yet the true prevalence is likely higher due to underdiagnosis, embarrassment and delayed presentation⁵. Around 60% of men experience a negative impact on quality of life with Peyronie's disease⁵, while treatment options during the acute phase remain limited and variable within clinical pathways.⁵

Early recognition is essential. During the acute phase, when inflammatory activity and symptom progression are most active, intervention may help limit scarring and deformity⁵. However, awareness of Peyronie's disease is somewhat limited, potentially contributing to delayed treatment of the condition.

A new injectable pathway for acute phase management

Perovial[®] is delivered via intrapenile injection over a 10–12-week treatment course⁶. The hyaluronic acid formulation with its antioxidative and antifibrotic properties is designed to soften plaque and support tissue remodelling, helping to slow or limit the progression of scarring⁶.

Clinical studies report improvements in penile curvature, plaque size and erectile function, with favourable patient satisfaction and a tolerable safety profile^{7,8,9}.

As the first hyaluronic acid injectable licensed for Peyronie's disease in the UK, Perovial[®] provides clinicians with a clear, accessible and structured intervention option ahead of chronic-

Registered Office

Sullivan House, 4-6
Colonial Business Park, Colonial Way,
Watford, Hertfordshire, WD24 4PR

Tel. +44 (0)1923 233 466
Registration number: 3929804

www.ibsapharma.co.uk
www.ibsagroup.com

stage surgical pathways. It also offers an alternative to other potential treatments with variable evidence bases, supporting a more consistent standard of care for patients.

Clinician perspective

Professor David Ralph, Professor of Urology, University College London, St Peter's Andrology, a UK urology Andrologist:

“Peyronie’s disease is often misunderstood, underdiagnosed and undertreated, partly because many men delay seeking help and partly because clinicians have had limited options to offer during the acute phase. The availability of a licensed hyaluronic acid injectable such as Perovial® provides a much-needed structured pathway for early intervention. Improving recognition of the acute phase and providing accessible treatment choices which could make a significant difference to long-term outcomes for many patients.”

Patient perspective

Kevin:

“Peyronie’s disease quietly crept into every part of my life and put real pressure on my relationship. I didn’t talk about it because I genuinely didn’t know where to turn, and that silence was incredibly isolating. Looking back, if I’d understood that the early signs needed prompt attention, I would have acted much sooner. Knowing there’s now a licensed treatment available in the early stages means men don’t have to sit in silence or wait until things worsen.”

– ENDS –

For further information:

Helen Pope PR – T: +44 (0)7879 818247 | E: helen@helenpopepr.co.uk

Notes to editors

Peyronie’s disease is a progressive fibrotic condition involving scar tissue formation within the tunica albuginea, often leading to penile curvature, pain, deformity, sexual dysfunction and psychological distress. Early identification of the acute phase remains essential to optimise care and guide timely referral.

References

1. NHS (2024). Peyronie’s disease. [[Peyronie's disease - NHS](#)] nhs.uk.
2. Peyronie’s Disease (2025). What is Peyronies Disease? [online] Peyronie’s Disease. Available at: <https://www.peyroniesdisease.co.uk/what-is-peyronies-disease/>.
3. Sandean, D.P. et al. (2024). *StatPearls*.
4. Al-Thakafi, S. & Al-Hathal, N. (2016). *Translational Andrology and Urology*.
5. British Dupuytren’s Society (2014). Peyronie’s treatments ([Peyronie's treatments | The British Dupuytren's Society](#)).
6. IBSA (2025). Perovial – Instructions for Use.
7. Favilla, V. et al. (2017). *Andrology*, 5(4), pp.771–775.
8. Cocci, A. et al. (2021). *World Journal of Men's Health*, 39(2), p.352.
9. Zucchi, A. et al. (2016). *Sexual Medicine*, 4(2), pp.e85–e90.

Job bag code: UKPVL00058

Date of Prep: January 2026

About IBSA

IBSA (*Institut Biochimique SA*) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.